Oncology Development Pipeline
We continue to build our treatment portfolio with a current focus on Oncology within the United States. Globally, our pipeline includes a robust portfolio of treatments for various therapeutic areas.
Research & development
overview
We invest in innovative research and development.
Servier is committed to investing in innovative research and development through our own internal pipeline or partnerships to best address the unmet needs of patients.
Our innovations
At Servier Pharmaceuticals, we are committed to making the world a better place for the patients we serve. Our innovative research focuses on four key therapeutic areas: Oncology, Cardiometabolism, Immune-Inflammatory and Neuroscience. Our extensive know-how and expertise position us to best address the unmet needs of patients. Servier draws on the excellence of its Research & Development (R&D) employees worldwide to develop effective treatment solutions.
Our Therapeutic Areas
Servier Pharmaceuticals is committed to reinvesting in research to help discover new treatments that improve our patients’ lives. To fuel the next generation of discovery, we are reinvesting more of our total revenue back into our own R&D and innovative partnerships than into life-cycle management. We are not interested in investing in incremental projects but are looking to invest in the big advances that truly move the needle for our patients.
According to the World Health Organization, cancer is the second leading cause of death worldwide, with one out of every six deaths stemming from cancer-related diseases. Cancer was also responsible for approximately 9.6 million deaths in 2018. We are targeting our oncology research on immuno-oncology, cellular metabolism, and apoptosis. Prioritized indications are hematological malignancies and solid tumors, such as gastrointestinal (colon, gastric and pancreas), breast and lung cancers, as well as cholangiocarcinoma and glioma.
Collaborations & Licenses
Our current collaborations and licenses include an emphasis on targeted protein degradation, epigenetic modifications, vectorization of BH3 mimetics, immuno-oncology modulators (small molecules, antibodies, IDH/MAT inhibitors) and CAR-T cell related technologies.
Partnerships
We are currently partnering with Allogene Therapeutics, BMS, Cellectis, Celsius, Institut Curie, IPSEN, Novartis, Pieris, Taiho Oncology, Vernalis, VHIO, and Walter and Eliza Hall Institute.
According to the World Health Organization, cardiovascular disease is the leading cause of death worldwide and diabetes is a progressive disease affecting 442 million people around the world. Servier is committed to the treatment of these pathologies. .
Collaborations & Licenses
Our current collaborations and licenses include an emphasis on Life Cycle Management (LCM) to capitalize on its medicine and expertise in incremental innovation, in particular by developing Single Pill Combinations (SPC). By simplifying treatments, these SPCs increase treatment compliance.
Partnerships
We are currently partnering with Amgen.
According to the National Institute of Health, over 10 percent of immune-inflammatory diseases are severe and do not respond to any treatment. We are targeting our immune-inflammatory research on lupus, primary Sjögren’s syndrome and systemic sclerosis as well as other chronic inflammatory and fibrotic diseases sharing similar pathophysiological mechanisms.
Collaborations & Licenses
Our current collaborations and licensing deals include an emphasis on autoimmune and fibrotic disorders.
Partnerships
We are currently partnering with Galapagos, ImmunoQure, and OSE Immunotherapeutics.
Based on data from the World Health Organization, more than one billion people are affected by neurological disease worldwide. We are targeting our neuroscience research on proteinopathies, characterized by abnormal accumulation of specific proteins such as Parkinson’s disease, autism, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), Huntington’s disease, and other rare diseases in neurodevelopmental and neurodegenerative disorders.
Collaborations & Licenses
Our current collaborations and licenses include an emphasis on sub-populations and rare forms of neurodegenerative disease.
Partnerships
We are currently partnering with Monash University, Neurochlore, Oncodesign, and Universitat Autonoma de Barcelona.
Therapies in development are being investigated for patient use and are not approved by the FDA.